Clinical trial
Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive…
NCT00294931 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00294931 |
|---|---|
| Title | Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer |
| Official title | A Phase II Trial of Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Small Cell Lung |
| Intervention type | Drug |
| Interventions | irinotecan, carboplatin, bevacizumab |
| Enrollment | 50 |
| Start date | Feb 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | Jan 1, 2009 |
| First posted | Feb 22, 2006 |
| Last update posted | Jun 28, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: